newsfilter
← Latest News
GlobeNewswire·

Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion

Encouraging data for CAD-1005 in Phase 2 HIT Study EOP2 scheduled for Q1 for top-priority indication Additional acute and chronic opportunities for 12-LOX inhibition beyond HIT PONTE VEDRA, Fla., March 02, 2026